428 related articles for article (PubMed ID: 27566596)
1. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.
Pecorelli A; Lenzi B; Gramenzi A; Garuti F; Farinati F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Cabibbo G; Felder M; Morisco F; Gasbarrini A; Baroni GS; Foschi FG; Biasini E; Masotto A; Virdone R; Bernardi M; Trevisani F;
Liver Int; 2017 Mar; 37(3):423-433. PubMed ID: 27566596
[TBL] [Abstract][Full Text] [Related]
2. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
3. Intermediate hepatocellular carcinoma: current treatments and future perspectives.
Dufour JF; Bargellini I; De Maria N; De Simone P; Goulis I; Marinho RT
Ann Oncol; 2013 Apr; 24 Suppl 2():ii24-9. PubMed ID: 23715940
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
6. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
Han K; Kim JH
World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
10. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience.
Varghese J; Kedarisetty C; Venkataraman J; Srinivasan V; Deepashree T; Uthappa M; Ilankumaran K; Govil S; Reddy M; Rela M
Ann Hepatol; 2017; 16(2):247-254. PubMed ID: 28233748
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
12. Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma.
Liu PH; Hsia CY; Lee YH; Hsu CY; Huang YH; Su CW; Lee RC; Lin HC; Huo TI
J Surg Oncol; 2015 Mar; 111(4):404-9. PubMed ID: 25643842
[TBL] [Abstract][Full Text] [Related]
13. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
[TBL] [Abstract][Full Text] [Related]
14. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
15. Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival.
Roberts SK; Gazzola A; Lubel J; Gow P; Bell S; Nicoll A; Dev A; Fink MA; Sood S; Knight V; Hong T; Paul E; Mishra G; Majeed A; Kemp W;
Scand J Gastroenterol; 2018; 53(10-11):1368-1375. PubMed ID: 30394145
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.
Ohki T; Kondo M; Karasawa Y; Kawamura S; Maeshima S; Kojima K; Seki M; Toda N; Shioda Y; Tagawa K
Adv Ther; 2017 May; 34(5):1097-1108. PubMed ID: 28389996
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hepatocellular carcinoma: beyond international guidelines.
Sangiovanni A; Colombo M
Liver Int; 2016 Jan; 36 Suppl 1():124-9. PubMed ID: 26725909
[TBL] [Abstract][Full Text] [Related]
18. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Chen L; Su H; Shao H; Xu K; Liang S; Liu J
Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
[TBL] [Abstract][Full Text] [Related]
20. Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model.
Chan YC; Kabiling CS; Pillai VG; Aguilar G; Wang CC; Chen CL
World J Surg; 2015 Jun; 39(6):1510-8. PubMed ID: 25665673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
